Additionally, as more GLP-1–based receptor agonists are being considered for weight loss in patients without diabetes, including those with obesity-related IBD, understanding their full safety spectrum becomes increasingly essential [19]. This evidence concerns the gene GCG and inflammatory bowel disease.